The expression and clinical significance of PANDAR in non-small cell lung cancer

聂　军; 周　波; 张郁林

doi:10.19401/j.cnki.1007-3639.2017.07.008

您当前的位置：

首页 >

文章列表页 >

The expression and clinical significance of PANDAR in non-small cell lung cancer

更新时间：2025-12-31

- The expression and clinical significance of PANDAR in non-small cell lung cancer
- China Oncology Vol. 27, Issue 7, Pages: 569-574(2017)
- 作者机构：
  
  三峡大学人民医院心胸外科,湖北,宜昌,443000
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2017.07.008
  CLC：
- Published Online：16 August 2017，
  
  Published：16 August 2017
- 稿件说明：
移动端阅览
聂　军,周　波,张郁林. 长链非编码RNA PANDAR在非小细胞肺癌中的表达和临床意义[J]. 中国癌症杂志, 2017, 27(7): 569-574.

聂　军, 周　波, 张郁林. The expression and clinical significance of PANDAR in non-small cell lung cancer[J]. China Oncology, 2017, 27(7): 569-574.
聂　军,周　波,张郁林. 长链非编码RNA PANDAR在非小细胞肺癌中的表达和临床意义[J]. 中国癌症杂志, 2017, 27(7): 569-574. DOI： 10.19401/j.cnki.1007-3639.2017.07.008.

聂　军, 周　波, 张郁林. The expression and clinical significance of PANDAR in non-small cell lung cancer[J]. China Oncology, 2017, 27(7): 569-574. DOI： 10.19401/j.cnki.1007-3639.2017.07.008.

摘要

背景与目的：长链非编码RNA(long non-coding RNA，lncRNA)在肿瘤的发生、发展过程中有重要作用。LncRNA CDKN1A反义链启动子DNA损伤激动RNA(promoter of CDKN1A antisense DNA damage activated RNA，PANDAR)与多种肿瘤的进展及预后相关。探讨非小细胞肺癌(non-small cell lung cancer，NSCLC)组织中lncRNA PANDAR的表达及临床意义。方法：采用实时荧光定量聚合酶链反应(real-time fluorescent quantitative polymerase chain reaction，RTFQ-PCR)方法检测94例新鲜NSCLC组织标本及相对应的癌旁组织标本中PANDAR的表达，分析其与NSCLC的临床病理特征、诊断价值和预后的关系。结果：PANDAR在NSCLC组织中的表达显著低于癌旁组织(P0.001)；PANDAR低表达和高表达组在肿瘤体积、淋巴结转移、疾病分期和分化程度方面差异均有统计学意义(χ

=9.197，P=0.002；χ

=7.126，P=0.008；χ

=6.271，P=0.012；χ

=8.147，P=0.004)；受试者工作特征(receiver operating characteristic，ROC)曲线的曲线下面积(area under the curve，AUC)为0.797(95%CI：0.614~0.849；P0.001)，灵敏度和特异度分别是49.8%和84.3%，Youden指数为0.402；PANDAR低表达和高表达组在总生存期(overall survival，OS)及无进展生存期(progression free survival，PFS)上的差异有统计学意义(χ

=7.282，P=0.007；χ

=6.777，P=0.009)。结论：PANDAR在NSCLC中低表达，可以作为NSCLC的新型生物标志物和诊断靶标。

Abstract

Background and purpose: Long non-coding RNA (lncRNA) is associated with carcinogenesis and cancer development. LncRNA promoter of CDKN1A antisense DNA damage activated RNA (PANDAR) was correlated with the progression and prognosis of various cancers. This study aimed to investigate the expression

and clinical significance of PANDAR in non-small cell lung cancer (NSCLC). Methods: Real-time fluorescence quantitative polymerase chain reaction (RTFQ-PCR) was used to detect PANDAR expression in 94 cases of NSCLC tissues and adjacent tissues. The association with patient clinic-pathological characteristics

diagnostic value and prognosis of PANDAR were further analyzed. Results: PANDAR expression was significantly downregulated in the NSCLC compared with adjacent tissues (P0.001). There was significant differences between tumor size

lymphatic metastasis

TNM stage and histologic differentiation in terms of PANDAR expression (χ

=9.197

P=0.002 4; χ

=7.126

P=0.008; χ

=6.271

P=0.012; χ

=8.147

P=0.004). The area under the curve (AUC) of receiver operating characteristic (ROC) curve was 0.797 (95%CI: 0.614-0.849; P0.001). The sensitivity and specificity were 49.8% and 84.3%

respectively. The index of Youden was 0.402. The differences between PANDAR low expression and high expression groups were statistically significant in overall survival time and progression free survival (χ

=7.282

P=0.007; χ

=6.777

P=0.009). Conclusion: The expression of PANDAR is down-regulated in patients with NSCLC and might prove useful as a biomarker for diagnosis and prognostic significance.

关键词

Keywords

references

Views

1556

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Advances and future perspectives of neoadjuvant immunotherapy in colorectal cancer

Research on high-throughput detection of plasma cell-free DNA for targeted therapy-related genes screening and prognosis prediction in non-small cell lung cancer patients

Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications

The progress and future prospects of the application of circulating tumor DNA in the diagnosis and treatment of gastric cancer

A study on prevention and treatment of chemotherapy induced nausea and vomiting in non-small cell lung cancer patients with low-frequency electrical stimulator for antiemesis

Related Author

Yuyang ZHANG

Qian LIU

Qiling DENG

Di SONG

Kexin XI

Xiaoting XIE

Xiaoyan WU

Wei ZHAO

Related Institution

Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine

BSL-3 Laboratory(Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University

Department of Pathology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Pancreatic and Gastric Surgery, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

AI问答

⁰